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Abstract: The use of ultrasound (US) and microbubbles (MB), usually referred to as sonoporation,
has great potential to increase the efficacy of chemotherapy. However, the molecular mechanisms
that mediate sonoporation response are not well-known, and recent research suggests that cell stress
induced by US + MBs may contribute to the treatment benefit. Furthermore, there is a growing
understanding that the effects of US + MBs are beyond only the cancer cells and involves the tumour
vasculature and microenvironment. We treated pancreatic cancer cells (MIA PaCa-2) and stromal cells,
fibroblasts (BJ) and human umbilical vein endothelial cells (HUVECs), with US ±MB, and investigated
the extent of uptake of cell impermeable dye (calcein, by flow cytometry), viability (cell count,
Annexin/PI and WST-1 assays) and activation of a number of key proteins in important intracellular
signalling pathways immediately and 2 h after sonoporation (phospho flow cytometry). Different cell
types responded differently to US ± MBs in all these aspects. In general, sonoporation induces
immediate, transient activation of MAP-kinases (p38, ERK1/2), and an increase in phosphorylation of
ribosomal protein S6 together with dephosphorylation of 4E-BP1. The sonoporation stress-response
resembles cellular responses to electroporation and pore-forming toxins in membrane repair and
restoring cellular homeostasis, and may be exploited therapeutically. The stromal cells were more
sensitive to sonoporation than tumoural cells, and further efforts in optimising sonoporation-enhanced
therapy should be targeted at the microenvironment.
Keywords: sonoporation; microbubbles; ultrasound; intracellular signaling; phosphorylation;
ultrasound contrast agents; drug delivery; cellular stress; pancreatic cancer; tumour microenvironment
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1. Introduction
The use of ultrasound (US) and microbubbles (MB) in combination with chemotherapy to increase
the efficacy of cancer therapy has gained interest in the last 20 years. The term “sonoporation”,
is often used to describe this phenomenon. The term describes the formation of pores that occur
when cells come into contact with MBs oscillating in an US field [1], hypothesised to enhance uptake
for co-administered chemotherapeutics [2]. However, there is still no consensus on what the exact
mechanisms underlying US + MBs enhanced cancer therapy are. Furthermore, the cellular stress
induced by US + MBs themselves has been proposed to contribute to the anti-cancer effects [3,4].
Despite the insufficient mechanistic understanding, substantial in vitro [5–13] and in vivo
research [5–9,14–17] has shown that US + MBs-enhanced cancer therapy is beneficial for cancer
therapy. In 2016, results from the first Phase 1 human clinical trial using US + MBs in combination
with chemotherapy to treat pancreatic ductal adenocarcinoma (PDAC) were published [18]. PDAC is a
deadly cancer, with less than an 8% five-year overall survival [19], which requires better treatment
options. The clinical trial demonstrated that the use of US + MBs is safe, and a secondary endpoint
indicated that sonoporation + chemotherapy (gemcitabine) may increase survival of patients. PDAC is
characterised by extensive desmoplastic stroma, thought to originate from cancer-associated fibroblasts
(CAFs), and a complex hypoxic tumour microenvironment, which are major contributors to resistance
to chemotherapy [19,20]. Some hypothesised effects of sonoporation on the tumour microenvironment
are increased drug extravasation from the blood vessels or destruction of tumour vasculature [2],
but the relevance of microenvironmental effects for the clinical efficacy of sonoporation remains
largely unknown.
In vitro sonoporation research has typically focused on cancer cell lines, evaluating the
sonoporation efficacy either by uptake of cell impermeable dyes [5,8,9,21] and/or by evaluation
of the viability of cells exposed to sonoporation [21] or sonoporation in combination with drugs [5–9,22].
Based on the fact that MBs are usually injected into the vasculature, in vitro studies have also addressed
the effects of sonoporation on endothelial cells, showing increased permeability both in the cellular
membrane [23,24] and interendothelial openings between cells [25–28].
Our previous study [4] using leukemic cells as a model system of cancer compared to healthy
peripheral blood cells demonstrated that different cell types have different sensitivities to sonoporation
in terms of molecular uptake, effect on viability and intracellular signalling. This was a simplified
system compared to solid tumours, which consist of the complex tumour microenvironment with
stromal cells, immune cells, fibroblasts, blood vessels and extracellular matrix (ECM) in addition to,
and supporting, the cancer cells [29]. The observed difference in sonoporation sensitivity raises the
question of whether the cell types within a solid tumour may also respond differently, meaning that
treatment of the cancer cells might not be the most important sonoporation effect in the enhancement
of chemotherapeutic efficacy. Investigations on the cellular responses to US + MBs should, therefore,
be carried out in cell types relevant for the tumour microenvironment.
In this study, we aim to improve our understanding of how sonoporation may affect pancreatic
cancer by evaluating the effects on the uptake of cell impermeable dye, viability and intracellular
signalling response in PDAC, endothelial and fibroblast cell types. The results from this study will
help expand our understanding of how the different cell types respond to sonoporation, which is
needed for the development of better in vitro and in vivo models for sonoporation, the optimisation of
sonoporation parameters and the choice of drugs. In fact, the results indicate that the cancer cells are
not the most sensitive to sonoporation in terms of uptake of cell-impermeable molecule, reduction in
viability or intracellular signalling response (phosphorylation of p38, ERK1/2, ribosomal protein S6
and 4E-BP1), further suggesting that cells in the tumour microenvironment may be relevant for
sonoporation efficacy.
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2. Materials and Methods
2.1. Chemicals
All chemicals were purchased from Merck KGaA (Darmstadt, Germany) unless otherwise stated.
2.2. Maintenance Cell Culture
Pancreatic ductal adenocarcinoma cell line MIA PaCa-2 (ATCC® CRM-CRL-1420TM,
kindly donated by Professor Anders Molven, University of Bergen, Bergen, Norway) was cultured
in high-glucose Dulbecco’s modified Eagle’s medium (DMEM #5671) supplemented with 10% foetal
bovine serum (FBS), 2% L-glutamine, 1 mM sodium pyruvate and 2.5% horse serum. Human foreskin
fibroblasts (BJ, ATCC® CRL-2522TM, kindly donated by professor Donald Gullberg, University of
Bergen, Bergen, Norway) were cultured in high-glucose DMEM #5671 supplemented with 10% FBS,
1% L-glutamine and 50 U/mL Penicillin/50 U/mL Streptomycin. Single-donor lot human umbilical
vein endothelial cells (HUVECs) (Cat#CC-2517, Lonza, Basel, Switzerland, kindly donated by Prof.
Jim Lorens, University of Bergen, Bergen, Norway) were cultured in EGMTM-2 medium supplemented
with EGMTM-2 Endothelial Cell Growth Medium-2 BulletKitTM (Lonza). Cell culture medium was
changed on the HUVECs every second day according to suppliers’ recommendations, except when
cultured in Petaka G3 LOT® (Celartia Ltd., Powell, OH, USA) [c.f. Section 2.4]. HUV-EC-Cs (ATCC®
CRL-1730TM) were cultured in F12-K medium (ATCC, Manassas, VA, USA) supplemented with
endothelial growth supplement from bovine neural tissue (#E2759) and 10% FBS. All cells were
cultured in a 5% CO2 humidified atmosphere at 37 ◦C.
2.3. Isolation of Cancer-Associated Fibroblasts (CAFs)
CAFs were isolated from cancer tissue biopsies of PDAC patients with primary lesions after
informed consent, and in accordance with the Declaration of Helsinki and approval by the Ethics
Committee (REK 2013/1772). In brief, tissues were collected and washed in Dulbecco’s modified
Eagle’s medium (DMEM #6429) supplemented with 2% antibiotic-antimycotic (AB/AM), 100 U/mL
penicillin, 100 µg/mL Streptomycin and 25 ng/mL Amphotericin B (Thermo Fischer Scientific, Waltham,
MA, USA). Bleeding and necrotic areas of the tissues were cut out using a sterile scalpel and washed
thoroughly. Tumour tissues were then cut into approximately 2–4 mm2 tissue bits and then transferred
onto a 10 cm culture dish, slightly air-dried (approximately 2 min) to allow explants to attach on
the growth surface of the dish, and incubated in FAD medium (DMEM/Nutrient Mixture F-12 Ham
supplemented with 10% FBS, 0.4 mg/mL hydrocortisone, 1% Insulin-Transferrin-Selenium, 50 mg/mL
L-ascorbic acid, 10 ng/mL epidermal growth factor and 1% AB/AM). Explants with an outgrowth of
cells with fibroblast morphology were trypsinized in a clonal ring placed around the respective explant
and fixed on the bottom of the dish with sterile vaseline and placed in 6-well plates. Isolated fibroblasts
were further characterised for lineage-specific markers: ESA, CD31, CD45 and CD140b for epithelial,
endothelial, blood-borne and mesenchymal origin, respectively. CAFs were further cultured in DMEM
(#6429) supplemented with 10% FBS and without AB/AM.
2.4. Cell Culture for Experiments
Three days prior to experiments, 26 mL of cell suspension was injected in Petaka G3 LOT®
(low oxygen transport) cell culture chambers (Figure 1a referred to as Petaka herein). A suitable
number of cells were injected to achieve confluency at the time of US/MB exposure. To avoid the
influx of air, the air valve on the Petakas was sealed with tape, and they were cultured in the
horizontal position for a minimum of 24 h to allow for cells to adhere to the plastic surface. The Petaka
chambers are designed for cell culture within a limited gas exchange and a gradually decreasing
oxygen concentration [30], which is closer to pO2 (“physioxia”) found in living tissue compared to the
“normoxic” conditions at atmospheric O2 pressure commonly used in vitro [31].
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The cells were exposed to US using a custom-made US treatment chamber (Figure 1), based on 
a previous design [32] and previously used in [22], suited for US exposure of adherent cells when 
cultured in Petakas. 
The US system consisted of 128, 9 × 6 mm PZ26 elements firing upwards as a plane-wave into 
the Petaka, ensuring US treatment of the entire cell-covered surface in the Petaka. The US transducers 
were driven by a custom Open Ultrasound system (Lecoeur Electronique, Chuelles, France). The 
acoustic field had been calibrated in three axes using a 200 µm needle hydrophone (Precision 
acoustics Ltd, Dorset, UK) in the fully assembled US chamber, and the Petaka was placed at the 
acoustic focus. 
 
Figure 1. (a) Drawing of cell culture bioreactor (Petaka) used for culturing of cells prior to ultrasound 
(US) treatment; (b) cutaway of custom-made US treatment chamber used for US treatment of cells 
(adapted from [22], Pharmaceutics, 2020). 
Before US treatment, air pockets were removed from the Petaka. To ensure that the floating MBs 
would come into contact with the cells, the Petaka was placed in the US treatment chamber (Figure 
1) with the cell-covered side on top, closest to the US absorber. A low-Mechanical Index (MI) (<0.01) 
B-mode scan was performed before treatment with US ± MB to detect air pockets in the US bath 
between the water medium and the Petaka. Air pockets, if present, were removed before US 
treatment. The US conditions used were based on a previous study [22] and referred to as “Medium 
US” or “High US” (see Table 1 for details). As untreated control, a Petaka, containing cells but no 
MBs, was placed in the US treatment chamber for 5 min without application of US. All experiments 
were performed in triplicate at minimum, except CAFs, where sonoporation experiments were only 
performed once and only treated with “High US”, due to limited material availability. Imaging of 
cells was performed immediately after sonoporation with 10× magnification using a Nikon Eclipse 
E200 microscope equipped with a Lumenera Infinity 1 camera. 
Figure 1. (a) Drawing of cell culture bioreactor (Petaka) used for culturing of cells prior to ultrasound
(US) treatment; (b) cutaway of custom-made US treatment chamber used for US treatment of cells
(adapted from [22], Pharmaceutics, 2020).
2.5. Microbubbles
SonazoidTM (GE Healthcare, Little Chalfont, UK) was reconstituted by adding 2 mL NaCl 9 mg/mL
(B Braun, Melsungen, Germany) and gently agitated for 30 s. MBs ere aspirated via a 19 G needle
and transferred to an eppendorf tube. A 19 G venting needle was used to avoid a pressure drop in the
vial. To ensure that the reconstituted bubbles were stable, Sonazoid™ bubbles were used within 1 h of
reconstitution. A 60 µL volume of reconstituted Sonazoid™ (1.2 × 109 bubbles/mL) was diluted in
NaCl 9 mg/mL to a total volume of 1 mL and injected into the Petaka immediately prior to US exposure,
giving a concentration of 2.8 × 106 bubbles/mL in the Petaka. In the untreated sample, and US alone
controls, 1 L of NaCl 9 mg/mL was added to Petaka. The Petakas were gently rolled in all directions
to ensure a homogenous distribution of MBs and NaCl.
2.6. In Vitro Treatment with Ultrasound and Microbubbles
The cells were exposed to US using a custom-made US treatment chamber (Figure 1), based on
a previous design [32] and previously used in [22], suited for US exposure of adherent cells when
cultured in Petakas.
The US system consisted of 128, 9 × 6 mm PZ26 elements firing upwards as a plane-wave into the
Petaka, ensuring US treatment of the entire cell-covered surface in the Petaka. The US transducers were
driven by a custom Open Ultrasound system (Lecoeur Electronique, Chuelles, France). The acoustic
field had been calibrated in three axes using a 200 µm needle hydrophone (Precision acoustics Ltd.,
Dorset, UK) in the fully assembled US chamber, and the Petaka was placed at the acoustic focus.
Before US treatment, air pockets were removed from the Petaka. To ensure that the floating
MBs would come into contact with the cells, the Petaka was placed in the US treatment chamber
(Figure 1) with the cell-covered side on top, closest to the US absorber. A low-Mechanical Index (MI)
(<0.01) B-mode scan was performed before treatment with US ±MB to detect air pockets in the US
bath between the water medium and the Petaka. Air pockets, if present, were removed before US
treatment. The US conditions used were based on a previous study [22] and referred to as “Medium
US” or “High US” (see Table 1 for details). As untreated control, a Petaka, containing cells but no
MBs, was placed in the US treatment chamber for 5 min without application of US. All experiments
were performed in triplicate at minimum, except CAFs, where sonoporation experiments were only
performed once and only treated with “High US”, due to limited material availability. Imaging of cells
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was performed immediately after sonoporation with 10×magnification using a Nikon Eclipse E200
microscope equipped with a Lumenera Infinity 1 camera.















Medium 2.00 80 1.8 22 0.2 50 2.7
High 2.00 160 3.6 22 0.378 358 9.64
2.7. Calcein Uptake
To assess if the cell membrane had been permeabilised, a nontoxic cell-impermeable fluorescent
dye, calcein, was added during treatment with US±MB. A 50 mg/mL calcein stock solution in 1 M NaOH
was kept at 2–8 ◦C protected from light. Immediately prior to treatment with US ±MB, calcein was
mixed with NaCl 9 mg/mL ±MBs in the 1 mL that was injected into the Petaka. A concentration of
6 µM calcein was used in all experiments.
After treatment with US ±MB, the cells were incubated for 1 h to allow for cell membrane pores
to re-seal [4,33], flushed twice with phosphate-buffered saline (PBS), detached using trypsin-EDTA
0.05% and harvested from the Petaka. Following centrifugation and resuspension in PBS, the cells
were analysed by flow cytometry on an Accuri C6 flow cytometer (BDBioscience, Franklin Lakes, NJ,
USA). Data collected from Acurri C6 were gated in FlowJo®, and the uptake of calcein was measured
as a percentage of calcein-positive cells. The gating strategy is shown in Supplementary Figure S1.
The median fluorescence intensity (MFI) of the cells in the calcein-positive population was also recorded.
2.8. Viability Analysis: Apoptosis and Cell Death
Cells were treated with US ± MBs and cultured in Petaka placed in a 5% CO2 humidified
atmosphere at 37 ◦C for 24 h. Following incubation, the medium from the Petaka was collected,
cells were flushed with phosphate-buffered saline (PBS) and the cells were detached from the plastic
using Accutase®. Harvested medium and cell suspension were combined, and cells were counted
using a haemocytometer (later referred to as cell count 24 h). Trypan Blue® (Thermo Fischer Scientific,
Waltham, MA, USA) was added to identify dead cells. Apoptosis was assessed by staining with
Annexin V antibody and propidium iodide (PI) using Dead cell Apoptosis kit with Annexin V Alexa
FluorTM 488 and Propidium Iodide (PI) (Invitrogen, Catalog #V12341, Thermo Fischer Scientific,
Waltham, MA, USA). The assay was performed in accordance with the manufacturer’s protocol with
two exceptions: Half the concentration of Annexin V antibody and of PI were used, based on titration,
and PI was added shortly before flow cytometry analysis. Data were collected on an Acurri C6 flow
cytometer and gated in FlowJo®. The gating strategy is shown in Figure S2.
To assess cell loss during US exposure (e.g., due to cell detachment or destruction), the cell count
per Petaka was counted using a haemocytometer at 0 h (as described in Section 2.10). As mentioned
above, cells were also counted after 24 h to assess sonoporation effects on viability. CAFs could
not be reliably counted in the haemocytometer, due to low cell concentration. CAFs were counted
24 h after US exposure by analysis of a fixed volume of cell suspension (300 µL) using an Accuri C6
flow cytometer.
2.9. Viability Analysis: Growth Potential and Metabolic Activity
Cells harvested from the Petaka 24 h post-sonoporation were used to assess their proliferative
capacity after re-seeding. Live cells (Trypan blue® negative) were seeded on 96-well cell culture plates
(MIA PaCa-2: 3000 cells, fibroblasts: 6000 cells, HUVEC: 3000 cells), and their metabolic activity was
assessed after 24, 48 and 72 h by addition of WST-1 reagent (Roche Diagnostics GmbH, Mannheim,
Germany). WST-1 was added 2 h before detection on a multiwell spectrophotometer in accordance to
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the manufacturer’s protocol. Live cells were also seeded on 24-well plates (MIA PaCa-2: 30,000 cells,
fibroblasts: 60,000 cells, HUVEC: 30,000 cells), and the cells were detached using Accutase®, diluted in
cell culture medium, and counted after 24, 48 and 72 h using a haemocytometer.
2.10. Sample Preparation for Phosphospecific Flow Cytometry
To investigate changes in intracellular signalling events, cells were harvested from separate
Petakas as soon as possible after sonoporation and after 2 h of incubation. Timepoints were selected
based on a previous study [4]. Cells cultured in separate Petakas were treated with 1 µM A23187
(calcium ionophore) + 100 nM phorbol myristate acetate (PMA: PKC activator) for 30 min as positive
controls for intracellular signalling. Cells were detached from the Petaka using the cold trypsin
method [34,35], i.e. with ice-cold 2.5% trypsin not containing ethylenediaminetetraacetic acid (EDTA).
Prior to cell detachment, the medium was harvested, the Petaka was flushed once with ice-cold
PBS, and the collected cell culture medium and PBS were placed on ice during detachment of cells.
Ice-cold 2.5% trypsin was added to the Petaka and subsequently placed on ice during the detachment
time. In all experiments, the cell detachment on ice started within 1–3 min after US exposure.
Cell detachment time varied between cell lines, as shown in Figure S3. Cell culture medium, PBS,
and cells were collected and fixed by adding 16% paraformaldehyde (PFA, Alfa Aesar, Haverhill, MA,
USA) directly to yield a final concentration of 2%, incubated for 15 min at room temperature and
permeabilised by adding ice-cold methanol [4,36]. Before addition of PFA, a sample was taken for cell
count (later referred to as cell count 0 h) and counted using a haemocytometer.
2.11. Barcoding
To reduce antibody staining variability, the samples were barcode-stained. The six individual cell
samples were stained with unique signatures of succinimidylesters of Pacific Blue and Pacific Orange
(barcoding) for multiplex flow cytometry [37]. After barcode-staining, the samples were washed in
PBS containing 1% bovine serum albumin and 2 mM EDTA, then pooled prior to antibody staining.
A graphical depiction of barcoding/sample preparation is shown in Figure S4: One barcode represents
all five samples from one timepoint in each experiment (Untreated cells, Medium US, High US,
Medium US + MBs, High US + MBs) and a positive control. Pooled cells were split into different
tubes and each tube was stained with an antibody panel. Each panel consisted of a combination of
two antibodies conjugated to either Alexa Fluor® 488 or 647 (Table S1). The panels of markers were
based on our previous study [4]: Mitogen-activated protein kinase (MAPK; p38 and extracellular
regulated kinase 1/2 (ERK1/2), cAMP response element-binding element (CREB), protein kinase A
(PKA), signal transducer and activator of transcription 3 (STAT3; 727 epitope), phosphoinositide
3-kinase (PI3K), Akt and mammalian target of rapamycin (mTOR) pathway proteins (ribosomal protein
S6) and eukaryotic translation initiation factor 4E-binding protein (4E-BP1). The panel was extended to
include focal adhesion kinase (FAK) and Src, based on studies on mechanotransduction in response to
US [38–40]. Samples were analysed on an LSR Fortessa flow cytometer (BD Bioscience, Franklin Lakes,
NJ, USA).
2.12. Data Analysis of Phosphospecific Flow Cytometry
Data collected on the LSR Fortessa were compensated, gated and de-barcoded in DIVA software.
The gating strategy is shown in Figure S5. Analysis of median fluorescence intensity (MFI) was
performed in Cytobank (Cytobank Inc., Santa Clara, CA, USA). The MFI of each sample was corrected
for autofluorescence of the cells and the barcode staining by subtraction of MFI of the corresponding
barcoded cells unstained with antibody. The arcsinh ratio (arcsinh (treated/5)−arcsinh (control/5)) was
calculated in Microsoft Excel to depict changes in phosphorylation.
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2.13. Statistical Analysis
Statistical comparisons were performed in GraphPad Prism 8 (San Diego, CA, USA).
A Shapiro-Wilk normality test was performed on all datasets to determine if the data were normally
distributed. As over 95% of the datasets passed the normality tests, a repeated-measures one-way
Analysis of Variance (ANOVA) with Holm–Sidak’s multiple comparison test of the sample MFI versus
the untreated samples was used. In addition, an ordinary ANOVA was used for statistical comparisons
of calcein uptake and viability (treated cells versus untreated cells; medium US + MBs vs. high
US + MBs only for % calcein-positive cells). Significance level was set at p-value 0.05.
3. Results
3.1. Direct Effects of Sonoporation: Uptake of Cell Impermeable Dye and Cell Lysis (Cell Count)
In all cell types, uptake of calcein was only observed when MBs were added, suggesting that
increased uptake only occurs after sonoporation. The lowest uptake was observed in MIA PaCa-2,
12% of cells at Medium US + MBs and 25% at High US + MBs (Figure 2a). In HUVECs, the percentage of
cells taking up calcein was high (70%) at both Medium and High US + MBs (Figure 2b). The percentage
of cells taking up calcein was even higher in fibroblasts, and increased with US intensity from
Medium US (79%) to High US (90%) (Figure 2c). The increase in US parameters from medium US
to high US had a significant effect on uptake in MIA PaCa-2 and fibroblasts (p < 0.001 and p < 0.01,







Figure 2. The percentage of cells taking up calcein. Addition of MBs was necessary for increased uptake
in cells. (a) In MIA PaCa-2, increased US intensity increased the percentage of calcein-positive cells.
(b) In human umbilical vein endothelial cells (HUVECs), increased US intensity was not important
for percentage of calcein-positive cells. (c) In fibroblasts, increased US intensity resulted in a small
increase in percentage of calcein-positive cells. Mean ± SEM; *** p < 0.001, **** p < 0.0001 (treated vs.
untreated cells).
The sonoporation parameters used in this study did not induce a reduction of cells (cell lysis) in
any of the cell lines used (Figure 3).
3.2. Cellular Viability upon Sonoporation
Sonoporation may induce apoptosis [41–44] and reduce proliferation of cells [4]. Sonoporation at
the US intensities in this study had minimal negative effects on the viability of MIA PaCa-2, HUVECs and
fibroblasts. In MIA PaCa-2, no increase in percentage of apoptotic cells were observed by Annexin/PI
staining (Figure 4a), although a small increase in dead cells at High US (p < 0.05) was observed
by Trypan Blue staining in samples taken directly after collecting cells and medium (Figure S6).
In HUVECs, apoptosis measured by Annexin V/PI staining increased with increasing US + MBs,
but this was not statistically significant (Figure 4b). The uptake of Trypan Blue in HUVECs at these
parameters was significantly different from untreated cells (p < 0.01) (Figure S6). In fibroblasts, a very
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small, but statistically significant (p < 0.05), increase in cell count was observed after 24 h of culturing






3 Figure 3. Cell count immediately (0 h) after sonoporation. Cell count (0 h) indicated no mechanical
destruction of cells in (a) MIA PaCa-2 and (c) fibroblasts, while a minor and nonsignificant reduction




4 Figure 4. Viability of cells harvested after 24 h of incubation in Petaka. (a) No significant reduction in the
cell count or increase in apoptotic AnnexinV/PI-stained cells of MIA PaCa-2 was observed. The metabolic
activity (WST-1) after re-seeding was not affected by US + MB. (b) Cell count 24 h post-sonoporation of
HUVECs is slightly, but not significantly, decreased in treated samples. Percentage of apoptotic cells
24 h post-sonoporation by AnnexinV/PI staining was increased, and also not statistically significant.
No significant change was observed in the metabolic activity (WST-1) of the cells after re-seeding of
the cells, although some reduction in metabolic activity was observed in cells exposed to US + MBs.
(c) No significant reduction in the cell count, increase in apoptotic AnnexinV/PI stained cells or reduced
metabolic activity (WST-1) after re-seeding of fibroblasts was observed. Mean ± SEM. * p < 0.05
(treated vs. untreated cells).
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The long-term viability after the re-seeding of cells was not significantly reduced in any of the cell
types (WST-1 in Figure 4, confirmed by cell counts in Figure S6). In HUVECs, there is a trend towards
reduced cell metabolic activity and growth after 48 h in cells treated with US + MBs, although this was
not significant.
3.3. Sonoporation Induced Changes in Intracellular Signalling
Sonoporation induced phosphorylation of MAP-kinases p38 T180/Y182 and ERK1/2 T202/Y204
in all three cell types, but with different magnitudes and timings (Figure 5a). The most pronounced
activation was observed in fibroblasts immediately after sonoporation, while the activation on MIA
PaCa-2 and HUVECs was weaker or delayed. In MIA PaCa-2, an immediate, weak activation of
both p38 T180/Y182 (Medium and High US + MBs; p = 0.15 (ns) and p < 0.05, respectively) and
ERK1/2 T202/Y204 (Medium and High US + MBs, p < 0.05 and p = 0.15 (ns), respectively) was
observed in cells treated with the combination of US + MBs (Figure 5a). p38 was still significantly
activated 2 h after sonoporation, but very weakly. In HUVECs, phosphorylation of p38 T180/Y182
was moderately increased in cells treated with US both with and without MBs immediately after
sonoporation, although this effect was only significant in cells treated without MBs (p < 0.05) (Figure 5a).
After 2 h, p38 T180/Y182 phosphorylation was still elevated, but lower than that at 0 h, in HUVECs
treated without bubbles (ns). In HUVECs treated with US + MBs, phosphorylation of p38 T180/Y182
was further increased 2 h after sonoporation (Medium US and High US + MBs; p < 0.01 and p = 0.08
(ns), respectively). ERK1/2 T202/Y204 phosphorylation was unchanged in HUVECs immediately
after sonoporation, but a small insignificant increase was observed 2 h after sonoporation in cells
treated with US + MBs. In fibroblasts, US + MBs induced significant, immediate changes in the
phosphorylation level of MAP-kinases p38 T180/Y182 (p < 0.05) and ERK1/2 T202/Y204 (p < 0.01) In
response to both Medium and High US (Figure 5a). Two hours after sonoporation, the phosphorylation
level was returned to the basal level. The phosphorylation of downstream target STAT3 S727 was not
significantly changed in any of the cell types, although STAT3 S727 was weakly increased immediately
and 2 h after sonoporation in fibroblasts.
In the mTOR pathway, 2 h after sonoporation, phosphorylation of ribosomal protein S6 was
increased in MIA PaCa-2 at the S240 epitope and in fibroblasts at both the S240 and the S235/236
epitopes (Figure 5b). However, phosphorylation of S6 was not statistically significant and varied
between experiments (Figure S7). Unlike the other cell lines, phosphorylation of ribosomal protein S6
was not increased at 2 h in HUVECs.
In general, sonoporation caused dephosphorylation of 4E-BP1 T36/45, particularly when MBs
were added (Figure 5b). In MIA PaCa-2, 4E-BP1 T36/45 was significantly dephosphorylated 2 h after
sonoporation using Medium US and Medium/High US + MBs (p < 0.05). Phosphorylation of 4E-BP1
T36/45 in HUVECs was decreased immediately using Medium US and High US + MBs (p < 0.05 and
p = 0.09 (ns), respectively), and at 2 h after using sonoporation High US + MBs (p < 0.05). In fibroblasts,
the dephosphorylation of 4E-BP1 T36/45 was most pronounced immediately after sonoporation MB
(Medium and High US + MBs; p < 0.001 and p < 0.0001, respectively). 4E-BP1 T36/45 was also
dephosphorylated in the fibroblasts in response to US without MBs, immediately after sonoporation
using Medium US (p < 0.05) and 2 h after using Medium and High US (p < 0.01 and p < 0.05,
respectively).
The only statistically significant change in phosphorylation of Akt S473 was observed in
MIA PaCa-2, 2 h after sonoporation, but this effect was very small (p < 0.05) (Figure 5b).
Changes in phosphorylation of CREB, PKA, Src and FAK, together with all experiments with CAFs,
were nonsignificant, and are presented in Supplementary data (Figures S8–S10).






Figure 5. Intracellular signalling induced by sonoporation. Heatmaps displaying changes in
phosphorylation status (shown as arcsinh ratio) of the chosen range of proteins in response to treatment
with US with and without SonazoidTM MBs. Phosphorylation status was detected immediately (0 h)
and 2 h post-sonoporation. Different phosphorylation profiles were observed in the (a) MAP-kinase
pathway (p38, ERK1/2 and downstream target STAT3 S727), and (b) mTOR (ribosomal protein S6 and
4E-BP1) and PI3K pathways (Akt). Mean ± SEM. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001
(treated vs. untreated cells).
3.4. Induction of Apoptosis by Inhibition of MEK/ERK in Combination with Sonoporation
The role of the ERK1/2 activation in response to sonoporation is not yet known, but has been
shown to be important for cellular recovery in cells exposed to pore-forming toxins through an
intracellular mechanism involving p38 and ERK1/2 (similar to observations in fibroblasts in Figure 5) [45].
Similar to Cabezas et al. [45], we treated cells with MEK/ERK inhibitor U0126 prior to sonoporation,
which increased the percentage of apoptotic fibroblasts (from 13% to 26%) and the percentage of
apoptotic HUVECs from 43% to 51% (Figure 6), but not at all in MIA PaCa-2. However, the increases
were only significant in HUVECs (p < 0.05).






Figure 6. Inhibition of MEK/ERK with U0126 in combination with high US + MBs increased the
percentage of apoptotic (b) HUVECs (p < 0.05) and (c) fibroblasts, but not (a) MIA PaCa-2. Mean ± SEM,
* p < 0.05 (treated vs. untreated cells).
4. Discussion
4.1. Sensitivity to Sonoporation
In this work, we aimed to compare the sonoporation efficacy and intracellular signalling responses
to sonoporation in a selection of cell lines representative of the cellular diversity present in solid
tumours. The uptake of calcein and other cell-impermeable dyes is commonly used in sonoporation
research as a measure of cell permeabilization and successful drug uptake [5,8,41,46–49]. The dye
uptake may be measured both as a percentage of stained cells and sonoporation efficiency (amount of
molecules taken up, measured as fluorescence intensity). In previous studies, the percentage of
stained cells and sonoporation efficiency followed the same trend [4,33], but contrary to expectations,
opposite trends were observed in percentage and efficiency (MFI) between the cell types in this study
(Figure 2 and Supplemental Figure S11). For the purpose of this discussion, we have focussed on
percentage calcein-stained cells (Figure 2), which is the most commonly used measure. Furthermore,
this measurement followed similar trends as the observed changes in intracellular signalling.
Interestingly, the cancerous MIA PaCa2 cells experienced a considerably lower percentage of
calcein-positive cells in both the medium and high US settings (12%/25%) compared to HUVECs
(70%/70%) and fibroblasts (79%/90%). Whilst high US + MB was shown to be most efficient in
sonoporation, the higher ultrasound intensity might lead to cell damage. However, the low-intensity
US regimen used in this study did not have a major impact on cell viability. It has previously been
concluded that cancerous cells may be more sensitive to US ±MB, both in terms of viability [50,51],
or viability and uptake of cell-impermeable dye [4], but the current results indicate that sonoporation
efficacy is not really a question of healthy versus cancer cells. In addition, different PDAC cancer cell
lines have different sensitivities to sonoporation, as shown by Bjånes et al. (Supplementary Data) [22].
Sonoporation efficacy has been associated with multiple factors. While larger cells have a greater
likelihood of interaction with microbubbles, additional factors might be more relevant [51]. This is
supported by our results on sonoporation efficacy in small HUVECs versus larger HUV-EC-C cells
(HUVEC cell line) (Figure S12) where the difference in uptake was not significant, and a larger
difference was actually observed between HUVECs and MIA PaCa-2 despite their similarity in cell size
(Figure S13). Cell membrane stiffness is also proposed to influence sonoporation [52], which should be
explored in further studies.
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4.2. Induction of Sonoporation Signalling
Activation of intracellular signalling follows a similar pattern as observed in our previous
study on a leukemic cell line and peripheral mononuclear blood cells (PBMCs) [4], suggesting a
general mechanism across cell types and irrespective of differences in the culturing of suspension
and adherent cell lines. In both studies, the magnitude of activation follows the trend of calcein
uptake (i.e. extent of permeabilisation). The most important pathways involved were activation of
the MAP-kinases p38 and ERK1/2 (and CREB, STAT3, Akt in [4]), and activation of either 4E-BP1
or eIF2α [4], and ribosomal protein S6 2 h post-sonoporation. Just as in MIA PaCa-2, the changes
in intracellular signalling previously observed were overall weaker in PBMCs [4], where a lower
proportion of cells were sonoporated.
No major impact on cell viability was observed in this study, except a small increase in apoptotic
fibroblasts and HUVECs when MEK/ERK was inhibited using U0126. The activation of MAP-kinase
(p38, ERK) and dephosphorylation of 4E-BP1 in response to sonoporation resembles signalling related
to membrane repair following pore formation and osmotic stress in cells exposed to pore-forming
toxins [45,53] and electroporation [54,55]. The similarity was most pronounced in fibroblasts,
which may explain why viability was not affected in the fibroblasts in spite of the high rate of
sonoporation (calcein uptake). The mechanism for repair of sonoporation-induced pores, i.e. repairable
sonoporation [56], is still not yet fully known but has also been compared by others to membrane repair
in cells exposed to pore-forming toxins [57]. The relationship between pore formation (by sonoporation,
pore-forming toxins, electroporation), signalling events and membrane repair requires further evidence
in future studies.
Dephosphorylation of 4E-BP1 is most commonly known to suppress protein synthesis through
inhibition of cap-dependent protein translation [58,59], which under stressful conditions, may be
regulated though the unfolded protein response (UPR) to restore cellular homeostasis [60]. However,
the sonoporation-inhibition of 4E-BP1 may itself contribute to the anti-cancer effects of sonoporation.
In PDAC therapy, inhibition of 4E-BP1 in cancer-associated fibroblasts was found to repress secretion
of proteins involved in chemoresistance, and to improve the efficacy of chemotherapy (gemcitabine)
by acting as a stroma-targeted therapy [61].
Together with dephosphorylation of 4E-BP1, sonoporation induced a paradoxical phosphorylation
of ribosomal protein S6 in the mTOR signalling pathway. The role of S6 activation in response to
sonoporation is not yet known, but we observed this activation to be absent under conditions where
cellular viability was decreased by sonoporation in our previous study on leukemic cells too [4].
Typically, activation of ribosomal protein S6 stimulates cap-dependent protein translation downstream
of mTOR [62]. The activation may imply that cellular homeostasis is restored, resulting in stimulated
protein synthesis, but further studies are required to confirm this.
4.3. Limitations of This Study and Future Perspectives
Whilst the effects of sonoporation on cancer cells have been extensively studied and, to some
extent, also on HUVECs, the effects on fibroblasts, cancer-associated fibroblasts and other cells of the
tumour microenvironment are less known. As these results show that the different cell types respond
differently to sonoporation, it is important to include the cells of the tumour microenvironment in
future studies. This study was limited by the inclusion of only one cell line for each cell type and
only one cancer cell line. Based on differences in sonoporation efficacy between PDAC cell lines [22]
differences in magnitude of signalling changes may be anticipated.
The main limitations are that each cell type was studied separately and cultured as a monolayer
on a plastic surface with no regulation of liquid flow, temperature or gas saturation. Cells were
cultured in Petaka G3 LOT cell culture chambers. Even though these are designed to regulate gas
exchange, pO2 depends on the cell line and cell counts, and a limitation in these experiments is that
pO2 was not monitored, as this parameter may affect both the physical properties of microbubbles and
viability/responses of the cells.
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Recent studies on interendothelial openings between cells [25–27] suggest that the effects of
sonoporation are beyond the simple formation of pores in cancer cells interacting with bubbles in
an US field. However, this was also studied on monolayers of endothelial cells alone. The term
“sonopermeation” has been introduced to cover the broader range of effects leading to increased
delivery of drugs, including endocytosis, opening of cellular junctions and changes in vessels and
the stromal compartment [63], but actual determinations of the role of different cell types and the
mechanism of sonoporation require more advanced organoid models or preclinical studies with
humanised immune systems and tumours. Furthermore, as the results in all cell lines in this study
confirm that MBs are essential for sonoporation, more advanced models are also required to assess
if MBs only affect the endothelium or if the reduced viability and opening of junctions between
endothelial cells can lead to interaction with the tumour microenvironment and cancer cells.
The majority of these studies have been performed in triplicate due to the complexity of the
technical process required to obtain results. This may impact the statistical analysis and potential
conclusions that can be drawn from this study. Further work and additional repetitions should be
performed to independently validate these results.
5. Conclusions
Different cell types respond differently to US + MBs, in terms of uptake of cell-impermeable dye,
reduction in viability and intracellular signalling. Sonoporation is associated with activation of the
MAP-kinases p38 and ERK, and increase in the phosphorylation of ribosomal protein S6 together
with dephosphorylation of 4E-BP1. This may be a stress-response for cells to survive and repair the
cell membrane after sonoporation, resembling cellular responses to electroporation and pore-forming
toxins, and are potential drug targets enhancing the efficacy of sonoporation in cancer therapy. As cell
types in the tumour microenvironment are more sensitive to sonoporation, further efforts in optimising
sonoporation-enhanced therapy should be targeted at the microenvironment.
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